Censo Biotechnologies and Cellectricon have joined forces to develop a first-in-kind humanized drug discovery platform to target chronic pain. The platform is based on human induced pluripotent stem cell–derived neurons in combination with Cellectricon's Cellaxess® Elektra screening system. The combination of highly functional screening with a human cell type of relevance for chronic pain has the potential to enable the generation of better drug candidates for this condition and other diseases.
Physiologically relevant human models of chronic pain are essential for the development of new therapeutics and to overcome poor translation between animal studies and the clinical setting1. In this Application Note, we describe how sensory neurons derived from human induced pluripotent stem cells (hiPSCs) with a relevant expression profile can be applied in screening to identify compounds that change a disease phenotype, such as neuronal excitability, rather than the activity of specific targets. We envision that the described platform could be used in clinical trials in a dish2, which could vastly improve the translation of drug candidates in human subjects with chronic pain and other devastating diseases.
Supply and differentiation of hiPSCs
HiPSCs were obtained from the European bank for induced pluripotent stem cells (EBiSC), and working banks of hiPSCs were produced. Each bank was then characterized by flow cytometry and morphology.
Differentiation was achieved in the Censo laboratories in Cambridge, UK, with a sensory neuronal differentiation protocol based on a publication by Young et al.3. In summary, fully characterized hiPSCs were seeded as single cells and at low confluence onto Matrigel. Induction of differentiation was achieved by dual SMAD inhibition with the small molecules SB431542 and LDN193189, followed by further neural commitment and patterning using DAPT, SU5402 and CHIR99021. Neural crest cells were cryopreserved, and quality control was performed to determine the quality and yield of neuronal cultures. Neural crest cells were matured into functioning neurons by the use of growth factors to facilitate sensory neuronal development.
Each cryopreserved batch of sensory neurons was quality controlled at the neural crest and sensory neuronal development stages. Figure 1 shows the typical quality control process carried out for each batch of hiPSC-derived sensory neuronal cells.
Immunocytochemistry was used to determine the protein-level expression of the peripheral nervous system marker SOX10 and the sensory neuronal marker BRN3A at day 46. At the gene-expression level, a panel of neural crest and sensory neuronal markers was used that included genes encoding developmental transcription factors such as NEUROG1, OTX2, TFAP2B, POU4F1 and ISL1. Furthermore, expression of genes encoding late sensory neuronal markers and important sensory neuronal targets was also measured. These genes included RUNX1, SCN9A, SCN10A, NTRK1 and TRPV1.
Quality control assessment, batch-to-batch consistency and assay reproducibility are all requirements for this platform technology, and for robust data generation.
High-quality cryopreserved and quality controlled sensory neuronal progenitor batches were provided to Cellectricon for the next stage of the process. The final stages of neuronal maturation were completed within the Cellectricon laboratories.
Functional drug screening in hiPSC-derived sensory neurons
The Cellaxess Elektra system enables electric field stimulation (EFS) and monitoring of neuronal cell cultures directly in 384-well microplates. Calcium imaging is used to monitor action potentials in cells during EFS while a homogeneous electrical field is applied. (Fig 2a).
The simultaneous EFS and imaging of the entire plate enables the identification of test compounds that modulate neuronal excitability in a high-capacity fashion while delivering electrophysiology-like accuracy. Physiological relevance is demonstrated by appropriate activity of clinically relevant tool compounds representing a wide range of mechanisms for chronic pain (Fig. 2b and Table 1).
Where applicable, the potencies align with effective plasma concentrations in chronic pain conditions4,5. Some variation was observed between lines from two individuals/assay replicates. It is therefore important to consider how many individuals need to be included in a screening strategy.
A major benefit of using hiPSC-derived neurons is that cell supply will no longer limit the throughput of the system, as is the case when using primary tissue. The assay presented here is fit for screening libraries of up to 50,000 compounds in a relatively short time frame and is accordingly suitable for supporting medium-throughput drug discovery campaigns.
Summary and conclusions
The data presented here show that that Cellectricon's Cellaxess Elektra system, when used in combination with hiPSC-derived sensory neurons produced by Censo, is well suited to investigate compound effects on neuronal excitability, with high relevance to human pain conditions. Because of the high capacity of the platform, we can generate highly refined compounds ready for clinical testing from medium-throughput compound libraries. We are now pleased to offer fully supported access to this first-in-kind humanized screening platform with the aim of identifying novel lead compounds with great potential for translation into new treatments for chronic pain.
Importantly, this platform is not limited to chronic pain. Censo provides cell-based models of disease using cells from a diverse range of tissue donors, and is specializing in the production of customer-specific or customer-generated hiPSC lines from large cohorts of individuals to create virtually any cell in the human body. Accordingly, Censo can provide hiPSC lines to support the development of new targeted treatments for disease in several therapeutic areas.
Moving forward, we also see potential for the use of this combination of technologies for 'clinical trials in a dish', which could vastly improve the translation of drug candidates in human subjects with chronic pain, neurodegenerative disorders and other devastating diseases.
Whiteside, G.T., Pomonis, J.D. & Kennedy, J.D. Neurosci. Lett. 557, 65–72 (2013).
Haston, K.M. & Finkbeiner, S. Annu. Rev. Pharmacol. Toxicol. 56, 489–510 (2016).
Young, G.T. et al. Mol. Ther. 22, 1530–1543 (2014).
Sivenius, J., Kalviainen, R., Ylinen, A. & Riekkinen, P. Epilepsia 32, 539–554 (1991).
Choi, Y., Han, H., Shin, D., Lim, K. S. & Yu, K.-S. Drug Des. Devel. Ther. 9, 4127–4135 (2015).
This article was submitted to Nature Methods by a commercial organization and has not been peer reviewed. Nature Methods takes no responsibility for the accuracy or otherwise of the information provided.
About this article
Cite this article
Tams, D., Karila, P. & Barnes, A. A humanized phenotypic screening platform for chronic pain. Nat Methods 14, 636 (2017). https://doi.org/10.1038/nmeth.f.401